SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 6, 1995
Eli Lilly and Company
- -----------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Indiana 1-6351 35-0470950
- ------------------------- -------------- -------------------
(State or other jurisdic- (Commission (IRS Employer
tion of incorporation) File Number) Identification No.)
Lilly Corporate Center, Indianapolis, Indiana 46285
- ------------------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (317) 276-2000
No Change
- ---------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 7. Financial Statements and Exhibits.
Exhibit
Number Exhibit
- -------- -------
(1) Form of Underwriting Agreement, dated as of
June 6, 1995, among Eli Lilly and Company and
Morgan Stanley & Co. Incorporated, Goldman
Sachs & Co., Merrill Lynch, Pierce, Fenner &
Smith Incorporated and J.P. Morgan Securities
Inc. relating to the issuance and sale by Eli
Lilly and Company of $500,000,000 aggregate
principal amount of its 7-1/8% Notes Due
2025.
(4) Forms of 7-1/8% Note Due 2025 (Book-Entry) were
filed with the Commission as Exhibit 1.1 to
registration statement on Form 8-A on June 8, 1995
and are incorporated herein by this reference.
(24) Consent of Ernst & Young LLP.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
ELI LILLY AND COMPANY
(Registrant)
By: /s/ Edwin W. Miller
-------------------
Edwin W. Miller
Vice President and
Treasurer
Dated: June 12, 1995.
3
Exhibit Index
Exhibit Description
Number of Exhibit Page
- -------- ----------- ----
(1) Form of Underwriting Agreement, dated as of
June 6, 1995 among Eli Lilly and Company and
Morgan Stanley & Co. Incorporated, Goldman
Sachs & Co., Merrill Lynch, Pierce, Fenner &
Smith Incorporated and J.P. Morgan Securities
Inc. relating to the issuance and sale by Eli
Lilly and Company of $500,000,000 aggregate
principal amount of its 7-1/8% Notes Due
2025.
(4) Forms of 7-1/8% Note Due 2025 (Book-Entry) were
filed with the Commission as Exhibit 1.1 to
registration statement on Form 8-A on June 9, 1995
and are incorporated herein by this reference.
(24) Consent of Ernst & Young LLP.
4
UNDERWRITING AGREEMENT
June 6, 1995
ELI LILLY AND COMPANY
Lilly Corporate Center
Indianapolis, Indiana 46285
Dear Sirs:
The undersigned (the "Underwriters") understand that
Eli Lilly and Company, an Indiana corporation (the "Company"),
proposes to issue and sell $500,000,000 aggregate principal
amount of 7 1/8% Notes Due 2025 (the "Notes").
Subject to the terms and conditions set forth or
incorporated by reference herein, the Company hereby agrees to
sell and the Underwriters agree to purchase, severally and not
jointly, the principal amount of the Notes and set forth below
opposite their names at a purchase price of 98.035% of the
principal amount thereof, plus accrued interest from June 1,
1995 to the date of payment and delivery:
Principal Amount
Name of Notes
---- ----------------
Morgan Stanley & Co. Incorporated $ 125,000,000
Goldman, Sachs & Co. 125,000,000
Merrill Lynch, Pierce, Fenner
& Smith Incorporated 125,000,000
J.P. Morgan Securities Inc. 125,000,000
-------------
Total . . . . . . $ 500,000,000
=============
The Underwriters will pay for the Notes upon
delivery thereof at the office of Morgan Stanley & Co.
Incorporated at 10:00 a.m. (New York time) on June 12, 1995,
or at such other time, not later than 5:00 p.m. (New York
time) on June 19, 1995, as shall be designated by the
Underwriters. The time and date of such payment and delivery
are hereinafter referred to as the Closing Date.
The Notes shall have the terms set forth in the
Prospectus dated June 1, 1995 and the Prospectus Supplement
dated June 6, 1995, including the following:
Maturity Date: June 1, 2025
Interest Rate: 7 1/8% per annum
Redemption Provisions: Not redeemable prior to maturity
Interest Payment Dates: December 1 and June 1 commencing
December 1, 1995 (interest accrues
from June 1, 1995)
Form and Denomination: Notes will be issued in the form of
global securities in the aggregate
principal amount of $500,000,000.
Specified Funds for and
Manner of Payment of
Purchase Price: Federal funds
Price to Public: 98.910%
All provisions contained in the document entitled
Eli Lilly and Company Underwriting Agreement Standard
Provisions (Debt Securities) dated March 18, 1993, a copy of
which is attached hereto, are herein incorporated by reference
in their entirety and shall be deemed to be a part of this
Agreement to the same extent as if such provisions had been
set forth in full herein, except that (i) if any term defined
in such document is otherwise defined herein, the definition
set forth herein shall control, (ii) all references in such
document to a type of security that is not a Note shall not be
deemed to be a part of this Agreement, (iii) all references in
such document to the "Manager" shall be deemed to refer to the
Underwriters, (iv) the several obligations of the Underwriters
are subject to the additional condition that the Notes shall
have been approved for listing on the New York Stock Exchange
subject to official notice of issuance and (v) the opinion
referred to in Section 4(c) shall be delivered by Daniel P.
Carmichael, Esq., Deputy General Counsel of the Company.
2
Please confirm your agreement by having an
authorized officer sign a copy of this Agreement in the space
set forth below.
Very truly yours,
MORGAN STANLEY & CO. INCORPORATED
GOLDMAN, SACHS & CO.
MERRILL LYNCH, PIERCE, FENNER
& SMITH INCORPORATED
J.P. MORGAN SECURITIES INC.
By: MORGAN STANLEY & CO. INCORPORATED
By: /s/ LAURIE CAMPBELL
------------------------------------
Name: Laurie Campbell
Title: Vice President
Accepted:
ELI LILLY AND COMPANY
By: /s/ EDWIN W. MILLER
------------------------------
Name: Edwin W. Miller
Title: Vice President and Treasurer
3
[LETTERHEAD]
CONSENT OF INDEPENDENT AUDITORS
We consent to the reference to our firm under the caption 'Experts' in the
Registration Statement (Form S-3 No. 33-58977) and related Prospectus Supplement
of Eli Lilly and Company for the registration of it 7 1/8% notes due June 1,
2025 and to the incorporation by reference therein of our report dated February
8, 1995, with respect to the consolidated financial statements of Eli Lilly and
Company incorporated by reference in its Annual Report (Form 10-K) for the year
ended December 31, 1994, filed with the Securities and Exchange Commission.
ERNST & YOUNG LLP
June 12, 1995